I agree, there’s real potential here, and the JMM presentation highlighted some exciting updates.
It’s great that the $20 million revenue estimate is seen as conservative—leaves room for upside.
On the capital raise, it could be beneficial in the long run. With cash flow positive expected in the second half of FY25, a raise now might set BXN up well for further expansion, especially into the UK market. Plus, with the GMP license, BXN is ready to scale production for growing demand in THC gummies and other products.
Once the raise is done and more Aussie deals are secured, we could see a solid market position. I’m curious—how quickly do you think BXN will move on the UK expansion?”
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.7¢ |
Change
-0.004(12.9%) |
Mkt cap ! $58.45M | |||
| Open | High | Low | Value | Volume |
| 3.1¢ | 3.2¢ | 2.7¢ | $249.2K | 8.379M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1096318 | 2.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.9¢ | 150000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| BXN (ASX) Chart |